![](https://www.molecular-medicine-israel.co.il/wp-content/uploads/2020/05/mosquito-malaria.jpg)
An open-label phase 1/2a trial of a genetically modified rodent malaria parasite for immunization against Plasmodium falciparum malaria
Abstract For some diseases, successful vaccines have been developed using a nonpathogenic counterpart of the causative microorganism of choice. The nonpathogenicity of the rodent Plasmodium berghei (Pb)